Article Hero

Inovio Pharmaceuticals halts COVID-19 vaccine trial

Miguel A. Rodriguez
Miguel A. Rodriguez
28 September 2020
Its shares plummeted more than 33% after the news

As the race for finding a viable COVID-19 vaccine is getting tougher, incidents start to show up. The latest pharmaceutical company to halt the trials after AstraZeneca is Inovio Pharmaceuticals.

Earlier today, the Pennsylvania-based company announced that Phase II of the clinical trial for its potential #COVID-19 #vaccine was in “partial clinical hold.” According to the company’s statement, the pause is caused by the Food and Drug Administration (#FDA) inquiry. 

At the moment, Inovio is working on answering the regulator’s questions, and the response will be available in October. Following the company’s response, the FDA has 30 days to decide if the trial can move forward or not. 

The news shocked the markets, and made Inovio stock price drop more than 33% during today’s pre-market session. Since the beginning of the year, the company’s stocks have increased 413.3%, while USA500 added 21%.

Read about AstraZeneca’s situation here!


This information/research prepared by Miguel A. Rodriguez does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. The research analyst primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views and consequently any person acting on it does so entirely at their own risk.The research provided does not constitute the views of KW Investments Ltd nor is it an invitation to invest with KW Investments Ltd. The research analyst also certifies that no part of his/her compensation was, is, or will be, directly, or indirectly, related to specific recommendations or views expressed in this report.The research analyst in not employed by KW Investments Ltd. You are encouraged to seek advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit that conforms to your specific investment objectives, financial situation, or particular financial needs before making a commitment to invest. The laws of the Republic of Seychelles shall govern any claim relating to or arising from the contents of the information/ research provided. 

Share this article

How did you find this article?


Read More

Miguel A. Rodriguez
Miguel A. Rodriguez
Financial Writer

Miguel worked for major financial institutions such as Banco Santander, and Banco Central-Hispano. He is a published author of currency trading books.